Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 205

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 205
---
-maker in making decisions regarding

resource allocation
and assessing performance. The Company and its chief operating decision-maker view the Company’s operations and manage its business
in one operating segment, which is the research and development of the Company’s drug candidates.

| k. | Legal and other contingencies: |

The Company
accounts for its contingent liabilities in accordance with ASC 450 “Contingencies”. A provision is recorded when it is both
probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions
are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other
information and events pertaining to a particular matter. As of July 23, 2024 and December 31, 2023, , the Company is not a party
to any litigation that could have a material adverse effect on the Company’s business, financial position, results of operations
or cash flows.

| l. | Basic and diluted loss per share: |

Basic loss
per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding
during the reporting period. Diluted loss per share is computed similarly to basic loss per share except that the weighted average number
of shares outstanding is increased to include additional shares from the assumed exercise of stock options and warrants, if dilutive.
The average number of shares is calculated by assuming that outstanding conversions were exercised and that the proceeds from such exercises
were used to acquire common shares at the average market price during the reporting period potentially dilutive common shares issuable
upon the exercise of warrants and options were not included in the computation of loss per share because their effect was anti-dilutive

<div align='center'>F-19</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

| m. | Share-based payment transactions: |

The Company
accounts for share-based compensation in accordance with ASC 718, “Compensation – Stock Compensation” (“ASC 718”),
which requires companies to estimate the fair value of equity-based payment awards on the date of grant. The value of the portion of
the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the statements of comprehensive
loss.

The Company
recognizes compensation expenses for the value of its awards granted based